rs373384814
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_152594.3(SPRED1):c.446G>A(p.Ser149Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000353 in 1,613,876 control chromosomes in the GnomAD database, including 7 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
NM_152594.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SPRED1 | NM_152594.3 | c.446G>A | p.Ser149Asn | missense_variant | 5/7 | ENST00000299084.9 | NP_689807.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SPRED1 | ENST00000299084.9 | c.446G>A | p.Ser149Asn | missense_variant | 5/7 | 1 | NM_152594.3 | ENSP00000299084.4 | ||
SPRED1 | ENST00000561317.1 | c.383G>A | p.Ser128Asn | missense_variant | 6/6 | 4 | ENSP00000453680.1 |
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 152168Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000825 AC: 207AN: 250830Hom.: 4 AF XY: 0.00109 AC XY: 148AN XY: 135556
GnomAD4 exome AF: 0.000372 AC: 543AN: 1461590Hom.: 7 Cov.: 39 AF XY: 0.000525 AC XY: 382AN XY: 727084
GnomAD4 genome AF: 0.000171 AC: 26AN: 152286Hom.: 0 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74466
ClinVar
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 01, 2018 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 03, 2021 | - - |
Legius syndrome Benign:2
Benign, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jul 07, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | - - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 17, 2017 | Variant summary: The SPRED1 c.446G>A (p.Ser149Asn) variant involves the alteration of a conserved nucleotide. The variant lies within the WH1/EVH1 domain and the PH domain-like domain (InterPro). 4/4 in silico tools predict a benign outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in the large control database ExAC in 113/123230 control chromosomes of all ethnicities, but was predominantly observed in the South Asian subpopulation at a frequency of 0.006663 (110/16510 with 3 homozygotes). This frequency is about 2665 times the estimated maximal expected allele frequency of a pathogenic SPRED1 variant (0.0000025), providing strong evidence that this is likely a benign polymorphism found primarily in the populations of South Asian origin. Two studies identified the variant in patient cohorts, one of which identified an unaffected father of the proband carrying the variant, showing lack of cosegregation (Messiaen_JAMA_2009). Additionally, functional studies that measured inhibition of MEK, ERK activation, FGF-induced Elk1 activation, Raf1 kinase activity and phosphorylation, and effect this variant on differentiation of PC12 cells show that this variant behaves similar to the WT control, in contrary to several truncating mutations also tested, suggesting the variant has no significant functional effect (Brems_Nat Genet_2007, Messiaen_JAMA_2009). Taken together, this variant is classified as benign. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at